Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer

References

• Waite KA, Eng C. From developmental disorder to heritable cancer: it's all in the BMP/TGFbeta family. Nat Rev Genet 2003; 4:763 - 773
   PubMed Web of Science ®Google Scholar
• Feng XH, Derynck R. Specificity and versatility in TGFβeta signaling through Smads. Annu Rev Cell Dev Biol 2005; 21:659 - 693
   PubMed Web of Science ®Google Scholar
• Wong AS, Leung PC. Role of endocrine and growth factors on the ovarian surface epithelium. J Obstet Gynaecol Res 2007; 33:3 - 16
   PubMed Web of Science ®Google Scholar
• Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA, et al. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am J Obstet Gynecol 1992; 166:676 - 684
   PubMed Web of Science ®Google Scholar
• Nilsson EE, Skinner MK. Role of transforming growth factor beta in ovarian surface epithelium biology and ovarian cancer. Reprod Biomed Online 2002; 5:254 - 258
   PubMedGoogle Scholar
• Yamada SD, Baldwin RL, Karlan BY. Ovarian carcinoma cell cultures are resistant to TGFbeta1-mediated growth inhibition despite expression of functional receptors. Gynecol Oncol 1999; 75:72 - 77
   PubMed Web of Science ®Google Scholar
• Baldwin RL, Tran H, Karlan BY. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factorbeta growth arrest independent of transforming growth factor beta/Smad signaling. Cancer Res 2003; 63:1413 - 1419
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kobayashi H, Suzuki M, Kanayama N, Terao T. Transforming growth factor-beta1-dependent urokinase upregulation and promotion of invasion are involved in Src-MAPK-dependent signaling in human ovarian cancer cells. J Biol Chem 2004; 279:8567 - 8576
   PubMed Web of Science ®Google Scholar
• Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC Jr, et al. Regulation of invasion of epithelial ovarian cancer by transforming growth factorbeta. Gynecol Oncol 2001; 80:245 - 253
   PubMed Web of Science ®Google Scholar
• Balch C, Fang F, Matei DE, Huang TH, Nephew KP. Minireview: epigenetic changes in ovarian cancer. Endocrinology 2009; 150:4003 - 4011
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415 - 428
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007; 128:683 - 692
   PubMed Web of Science ®Google Scholar
• Li B, Carey M, Workman JL. The role of chromatin during transcription. Cell 2007; 128:707 - 719
   PubMed Web of Science ®Google Scholar
• Chan MW, Huang YW, Hartman-Frey C, Kuo CT, Deatherage D, Qin H, et al. Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia 2008; 10:908 - 919
   PubMed Web of Science ®Google Scholar
• Leu YW, Yan PS, Fan M, Jin VX, Liu JC, Curran EM, et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 2004; 64:8184 - 8192
   PubMed Web of Science ®Google Scholar
• Ren M, Pozzi S, Bistulfi G, Somenzi G, Rossetti S, Sacchi N. Impaired retinoic acid (RA) signal leads to RARbeta2 epigenetic silencing and RA resistance. Mol Cell Biol 2005; 25:10591 - 10603
   PubMed Web of Science ®Google Scholar
• Qin H, Chan MW, Liyanarachchi S, Balch C, Potter D, Souriraj IJ, et al. An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules. BMC Syst Biol 2009; 3:73
   PubMed Web of Science ®Google Scholar
• Chou JL, Su HY, Chen LY, Liao YP, Hartman-Frey C, Lai YH, et al. Promoter hypermethylation of FBXO32, a novel TGFbeta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest 2010; 90:414 - 425
   PubMed Web of Science ®Google Scholar
• Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821 - 9826
   PubMed Web of Science ®Google Scholar
• Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008; 68:4311 - 4320
   PubMed Web of Science ®Google Scholar
• Davis JN, McGhee L, Meyers S. The ETO (MTG8) gene family. Gene 2003; 303:1 - 10
   PubMed Web of Science ®Google Scholar
• Guo C, Hu Q, Yan C, Zhang J. Multivalent binding of the ETO corepressor to E proteins facilitates dual repression controls targeting chromatin and the basal transcription machinery. Mol Cell Biol 2009; 29:2644 - 2657
   PubMed Web of Science ®Google Scholar
• Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, et al. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer. Cancer Res 2006; 66:8404 - 8412
   Google Scholar
• Evangelou A, Letarte M, Jurisica I, Sultan M, Murphy KJ, Rosen B, et al. Loss of coordinated androgen regulation in nonmalignant ovarian epithelial cells with BRCA1/2 mutations and ovarian cancer cells. Cancer Res 2003; 63:2416 - 2424
   PubMed Web of Science ®Google Scholar
• Dumont N, Wilson MB, Crawford YG, Reynolds PA, Sigaroudinia M, Tlsty TD. Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers. Proc Natl Acad Sci USA 2008; 105:14867 - 14872
   PubMed Web of Science ®Google Scholar
• Chou JL, Chen LY, Lai HC, Chan MW. TGFbeta: friend or foe? The role of TGFbeta/SMAD signaling in epigenetic silencing of ovarian cancer and its implication in epigenetic therapy. Expert Opin Ther Targets 2010; 14:1213 - 1223
   PubMed Web of Science ®Google Scholar
• Vikhanskaya F, Erba E, D'Incalci M, Broggini M. Introduction of wild-type p53 in a human ovarian cancer cell line not expressing endogenous p53. Nucleic Acids Res 1994; 22:1012 - 1017
   PubMed Web of Science ®Google Scholar
• Shin KS, Sullenger BA, Lee SW. Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. Mol Ther 2004; 10:365 - 372
   PubMed Web of Science ®Google Scholar
• Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RC, Kelly KF, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 53:2128 - 2132
   PubMed Web of Science ®Google Scholar
• Okamoto A, Sameshima Y, Yokoyama S, Terashima Y, Sugimura T, Terada M, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991; 51:5171 - 5176
   PubMed Web of Science ®Google Scholar
• Tonks A, Pearn L, Musson M, Gilkes A, Mills KI, Burnett AK, et al. Transcriptional dysregulation mediated by RUNX1-RUNX1T1 in normal human progenitor cells and in acute myeloid leukaemia. Leukemia 2007; 21:2495 - 2505
   PubMed Web of Science ®Google Scholar
• Liu S, Shen T, Huynh L, Klisovic MI, Rush LJ, Ford JL, et al. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia. Cancer Res 2005; 65:1277 - 1284
   PubMed Web of Science ®Google Scholar
• Watabe T, Miyazono K. Roles of TGFbeta family signaling in stem cell renewal and differentiation. Cell Res 2009; 19:103 - 115
   PubMed Web of Science ®Google Scholar
• Bierie B, Stover DG, Abel TW, Chytil A, Gorska AE, Aakre M, et al. Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res 2008; 68:1809 - 1819
   PubMed Web of Science ®Google Scholar
• Tang Y, Kitisin K, Jogunoori W, Li C, Deng CX, Mueller SC, et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGFbeta and IL-6 signaling. Proc Natl Acad Sci USA 2008; 105:2445 - 2450
   PubMed Web of Science ®Google Scholar
• Tang B, Yoo N, Vu M, Mamura M, Nam JS, Ooshima A, et al. Transforming growth factorbeta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model. Cancer Res 2007; 67:8643 - 8652
   PubMed Web of Science ®Google Scholar
• Kulasingam V, Pavlou MP, Diamandis EP. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat Rev Cancer 2010; 10:371 - 378
   PubMed Web of Science ®Google Scholar
• Bertelsen K, Holund B, Andersen JE, Nielsen K, Stroyer I, Ladehoff P. Prognostic factors and adjuvant treatment in early epithelial ovarian cancer. Int J Gynecol Cancer 1993; 3:211 - 218
   PubMed Web of Science ®Google Scholar
• Chan MW, Wei SH, Wen P, Wang Z, Matei DE, Liu JC, et al. Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res 2005; 11:7376 - 7383
   Google Scholar
• Wei SH, Balch C, Paik HH, Kim YS, Baldwin RL, Liyanarachchi S, et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 2006; 12:2788 - 2794
   PubMed Web of Science ®Google Scholar
• Ahluwalia A, Yan P, Hurteau JA, Bigsby RM, Jung SH, Huang TH, et al. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol 2001; 82:261 - 268
   PubMed Web of Science ®Google Scholar
• Wei SH, Chen CM, Strathdee G, Harnsomburana J, Shyu CR, Rahmatpanah F, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002; 8:2246 - 2252
   PubMed Web of Science ®Google Scholar
• Gillan L, Matei D, Fishman DA, Gerbin CS, Karlan BY, Chang DD. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V) beta(5) integrins and promotes cell motility. Cancer Res 2002; 62:5358 - 5364
   PubMed Web of Science ®Google Scholar
• Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T. BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics 2005; 21:4067 - 4068
   PubMed Web of Science ®Google Scholar
• Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003; 35:146 - 150
   PubMed Web of Science ®Google Scholar
• Cheng AS, Jin VX, Fan M, Smith LT, Liyanarachchi S, Yan PS, et al. Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell 2006; 21:393 - 404
   PubMed Web of Science ®Google Scholar